Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19.
Administration, Inhalation
Anti-Inflammatory Agents
/ therapeutic use
Anticoagulants
/ therapeutic use
Antiviral Agents
/ therapeutic use
Betacoronavirus
COVID-19
Coronavirus Infections
/ drug therapy
Drug Repositioning
Heparin
/ therapeutic use
Humans
Pandemics
Pneumonia, Viral
/ drug therapy
SARS-CoV-2
COVID-19
Inhalation
SARS-CoV-2
heparin
pulmonary coagulation
Journal
Clinical medicine (London, England)
ISSN: 1473-4893
Titre abrégé: Clin Med (Lond)
Pays: England
ID NLM: 101092853
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
31
8
2020
medline:
1
12
2020
entrez:
1
9
2020
Statut:
ppublish
Résumé
Here, we advocate a highly favourable opportunity for the treatment of COVID-19 disease by repurposing a long-serving medical agent with an excellent history of clinical use, namely heparin. Heparin is best known as an anticoagulant, but it also exhibits direct antiviral activity against many enveloped viruses and has anti-inflammatory activity. The high incidence of thromboembolic events in COVID-19 patients suggests that coagulopathy plays an important role in the SARS-CoV-2 pathogenesis. This already makes heparin a unique, potentially curative agent that can be used immediately to help resolve the ongoing crisis associated with SARS-CoV-2 infection and COVID-19 disease. We demonstrate here
Identifiants
pubmed: 32863274
pii: clinmed.2020-0351
doi: 10.7861/clinmed.2020-0351
pmc: PMC7687307
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Anticoagulants
0
Antiviral Agents
0
Heparin
9005-49-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e218-e221Informations de copyright
© 2020 Royal College of Physicians 2020. All rights reserved.
Références
Ann Transl Med. 2017 Nov;5(22):444
pubmed: 29264361
Crit Rev Immunol. 1992;12(1-2):17-46
pubmed: 1418604
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Eur Respir J. 2001 Jan;17(1):36-8
pubmed: 11307751
Crit Care Med. 2003 Apr;31(4 Suppl):S329-36
pubmed: 12682461
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Eur Respir J. 2020 Jul 30;56(1):
pubmed: 32398297
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Antiviral Res. 2020 Sep;181:104873
pubmed: 32653452
Crit Care. 2008;12(3):R64
pubmed: 18460218
Cell Mol Immunol. 2016 Jul;13(4):432-42
pubmed: 27041635
J Aerosol Med Pulm Drug Deliv. 2010 Jun;23(3):161-72
pubmed: 20109123
Adv Drug Deliv Rev. 2018 Aug;133:5-18
pubmed: 29653129
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
J Virol. 2020 Nov 10;:
pubmed: 33173010
PLoS One. 2011;6(8):e23710
pubmed: 21887302
Thromb Res. 2008;122(6):743-52
pubmed: 17727922
Thromb Res. 2015 Dec;136(6):1059-66
pubmed: 26475409
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Clin Transl Sci. 2020 Sep 3;:
pubmed: 32881340
Nat Rev Drug Discov. 2020 Mar;19(3):149-150
pubmed: 32127666
Handb Exp Pharmacol. 2012;(207):281-305
pubmed: 22566229
Emerg Infect Dis. 2004 Mar;10(3):413-8
pubmed: 15109406
Burns. 2011 Nov;37(7):1154-60
pubmed: 21816542
World J Emerg Surg. 2020 Apr 20;15(1):29
pubmed: 32312290
Crit Care Med. 2014 Feb;42(2):413-9
pubmed: 24158173
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
Clin Med (Lond). 2020 Jul;20(4):e76-e81
pubmed: 32423903
Science. 2020 May 29;368(6494):945-946
pubmed: 32385100
N Engl J Med. 2020 May 21;382(21):2063
pubmed: 32294374
Crit Care. 2010;14(5):R180
pubmed: 20937093
Respir Med. 2000 Feb;94(2):174-5
pubmed: 10714425
Pharmaceuticals (Basel). 2016 Jul 04;9(3):
pubmed: 27384570
Science. 2020 Apr 24;368(6489):356-360
pubmed: 32327580